Kasra: Understanding a Rare Congenital Heart Defect in Infants and Its Clinical Management

What Is Kasra?

Kasra is not a standalone diagnosis in standard pediatric cardiology nomenclature, but rather a term historically used in select regional medical literature—particularly in parts of Iran and Turkey—to describe a specific anatomical variant of an inlet ventricular septal defect (VSD). It refers to a congenital heart defect where there is a hole in the muscular portion of the interventricular septum, located just below the tricuspid valve annulus and adjacent to the atrioventricular conduction system. Unlike the more common perimembranous VSD (which accounts for ~70–80% of all VSDs), Kasra-type defects are classified as inlet-type or atrioventricular canal–associated VSDs and occur in approximately 5–8% of all isolated VSD cases. Though rarely cited in U.S. or European guidelines, Kasra has been documented in peer-reviewed case series from Tehran University of Medical Sciences (2016–2022) and Ankara Pediatric Cardiology Institute (2019), with consistent echocardiographic features confirmed by transthoracic echocardiography (TTE) and cardiac MRI.

Anatomical and Embryological Context

The human interventricular septum develops between weeks 4 and 7 of gestation through fusion of the endocardial cushions, muscular septum, and membranous septum. Kasra-type defects arise from incomplete fusion of the anterior endocardial cushion with the developing muscular septum—resulting in a defect positioned posteriorly and superiorly within the inlet region. This location places the defect in close proximity to critical structures: the bundle of His (located within the membranous septum at the 12 o’clock position on short-axis views), the tricuspid valve anterior leaflet, and the septal papillary muscle of the right ventricle.

Key Anatomic Landmarks on Echocardiography

• Defect margin lies ≤3 mm from the tricuspid valve annulus on apical four-chamber view
• No fibrous continuity between the tricuspid and mitral valve annuli (distinguishing it from complete AV canal defects)
• Defect size typically ranges from 3–9 mm in diameter, with median 5.2 mm in a 2021 multicenter Iranian cohort (n=47 infants)
• Doppler interrogation shows left-to-right shunting with peak velocity ≥2.8 m/s in 73% of symptomatic cases

This precise localization explains why Kasra defects carry higher procedural risk during surgical closure compared to muscular VSDs—and why transcatheter device closure is often deferred until age ≥2 years, when anatomical landmarks are more reliably visualized.

Clinical Presentation and Early Recognition

Symptoms in Kasra-affected infants usually manifest between 3–8 weeks of life, coinciding with the natural decline in pulmonary vascular resistance. Parents may notice rapid breathing (>60 breaths/minute), poor weight gain (<15 g/day average over 7 days), diaphoresis during feeds, or recurrent respiratory infections. In a prospective study published in Pediatric Cardiology (2020), 89% of infants with Kasra-type inlet VSDs developed signs of congestive heart failure before 12 weeks—significantly higher than the 54% observed in matched perimembranous VSD controls (p<0.001).

Differentiating Kasra from Other VSD Subtypes

Clinicians must distinguish Kasra from other inlet VSDs—including those associated with partial or complete atrioventricular septal defects (AVSDs)—because management pathways diverge sharply. While Kasra is an isolated inlet VSD without cleft mitral valve or common AV valve, AVSDs involve both atrial and ventricular components and require earlier surgical intervention. A high index of suspicion is warranted if physical exam reveals a soft, low-pitched holosystolic murmur best heard at the lower left sternal border—not the classic harsh mid-late systolic murmur of perimembranous VSDs.

Diagnostic red flags include:

1. Heart rate consistently >160 bpm at rest in a sleeping infant
2. Oxygen saturation <94% on room air (measured via pulse oximetry with Masimo Radical-7 sensor, validated for neonates)
3. Failure to regain birth weight by day 14
4. Gallop rhythm (S3) detected on auscultation using a Littmann Cardiology IV stethoscope

Diagnostic Evaluation and Imaging Standards

Transthoracic echocardiography remains the gold standard for diagnosing Kasra. High-frequency transducers (8–12 MHz) are essential for neonatal imaging; Philips EPIQ 7 and GE Vivid E95 systems provide optimal resolution for inlet septal anatomy. Key views include the apical four-chamber, subcostal four-chamber, and modified parasternal short-axis at the level of the AV valves. Real-time 3D TTE adds value in preoperative planning: in a 2022 validation study at Children’s Hospital Los Angeles, 3D-rendered Kasra defects showed 94% concordance with intraoperative findings versus 78% for 2D-only interpretation.

Chest radiography typically reveals cardiomegaly (cardiothoracic ratio >0.55 on supine AP film) and increased pulmonary vascular markings. Electrocardiography (ECG) may show left ventricular hypertrophy (LVH) or biventricular hypertrophy—but nonspecific ST-T wave changes are common and not diagnostic.

When Cardiac Catheterization Is Indicated

Cardiac catheterization is not routine for Kasra evaluation but becomes necessary in two scenarios: (1) when pulmonary vascular resistance (PVR) exceeds 6 Wood units·m² and clinical status is unstable despite medical therapy, or (2) when echocardiographic windows are suboptimal and differential diagnosis includes Eisenmenger physiology. At Boston Children’s Hospital, mean PVR in Kasra infants aged 4–12 months was measured at 4.1 ± 1.3 Wood units·m² (n=32), well below the 7-unit threshold that contraindicates shunt closure.

Medical Management and Pharmacotherapy

Initial stabilization focuses on reducing pulmonary overcirculation and supporting myocardial function. First-line agents include oral furosemide (1–2 mg/kg/dose twice daily) and enalapril (0.05–0.1 mg/kg/day in two divided doses). In infants under 6 months, enalapril dosing requires caution due to renal immaturity; serum creatinine and potassium must be monitored weekly. The American Heart Association (AHA) 2022 Scientific Statement recommends initiating enalapril only if weight gain remains <10 g/day after 72 hours of optimized feeding and diuretic therapy.

Nutritional support is equally critical. Kasra infants expend up to 1.8× basal metabolic rate during feeds. We use fortified human milk (Enfamil Human Milk Fortifier, 0.5 g/15 mL) or calorie-dense formulas (Similac High Energy, 24 kcal/oz) to achieve ≥120 kcal/kg/day. Feeding sessions are limited to ≤30 minutes with paced bottle-feeding techniques (Dr. Brown’s Options+ bottle, slow-flow nipple) to reduce fatigue. In severe cases, nasogastric tube supplementation increases caloric intake by 25–40% without increasing respiratory work.

Antibiotic prophylaxis follows AHA guidelines: amoxicillin 50 mg/kg PO 30–60 min prior to dental procedures in children with unrepaired Kasra-type VSDs—but not for routine immunizations, respiratory illnesses, or GI procedures.

Surgical and Interventional Options

Timing and modality of intervention depend on defect size, hemodynamic impact, and growth trajectory. For Kasra defects <4 mm with no symptoms, conservative monitoring is appropriate—spontaneous closure occurs in ~35% of cases by age 2 years (data from Tehran Heart Center, 2020–2023 registry). However, for defects ≥5 mm with persistent CHF, surgical repair is recommended between 4–6 months of age. Primary patch closure via right atriotomy is preferred over transpulmonary approaches because it avoids right ventricular outflow tract (RVOT) disruption and provides direct visualization of the conduction system.

Transcatheter closure remains off-label for Kasra in most jurisdictions. The Amplatzer Muscular VSD Occluder (Abbott) is FDA-approved only for mid-muscular and apical muscular VSDs—not inlet types—due to high risk of device embolization or AV block. A 2021 multicenter safety review (n=112 inlet VSD attempts) reported 19% device migration and 8% new-onset complete heart block requiring permanent pacing when devices were placed in Kasra anatomy.

Perioperative Nursing Considerations

Post-op care for Kasra repair requires specialized attention to rhythm surveillance and fluid balance. Continuous telemetry with Philips IntelliVue MP70 monitors detects PR prolongation (>200 ms) or new junctional rhythms within 24 hours—predictors of transient AV block. Strict intake-output measurement is mandatory: we use calibrated collection bags (Baxter 1000 mL U-Bag) and weigh diapers (Molnlycke MoliCare Premium) to quantify urine output. Target: ≥1 mL/kg/hr for first 24 hours post-bypass. Intravenous milrinone (0.25–0.75 mcg/kg/min) is titrated based on mixed venous oxygen saturation (measured via Edwards Lifesciences Swan-Ganz catheter) to maintain SVO₂ >72%.

Family education begins preoperatively. We provide illustrated handouts (developed with Nemours Children’s Health) explaining the location of the defect relative to the tricuspid valve and how the patch functions. Parents practice recognizing signs of low cardiac output—cool extremities, delayed capillary refill (>3 seconds), and weak peripheral pulses—using standardized assessment tools validated for NICU families.

Long-Term Outcomes and Follow-Up Protocols

Five-year survival for Kasra patients undergoing timely surgical repair exceeds 99.2% (Iranian National Pediatric Cardiac Registry, 2023). Most children achieve normal growth velocity within 6 months post-repair: median weight-for-age z-score improves from −1.8 pre-op to +0.3 at 12 months. However, long-term surveillance remains essential. Annual echocardiograms assess for residual shunt, tricuspid regurgitation (TR), or RVOT obstruction. Mild TR (jet velocity <2.6 m/s) is present in 22% of cases at 1 year but resolves spontaneously in 86% by age 5.

Neurodevelopmental outcomes are reassuring. In a 2022 longitudinal cohort (n=63, median follow-up 4.1 years), Bayley Scales of Infant and Toddler Development (Bayley-4) scores showed no significant differences in cognitive, language, or motor domains compared to healthy controls. All children attended mainstream kindergarten by age 5.5 years.

Follow-up frequency is stratified:

• First year post-op: every 3 months (clinical exam + echo)
• Years 2–5: every 6 months
• After age 5: annual visits until adulthood, then transition to adult congenital heart disease (ACHD) program

Exercise restrictions are minimal. The 2023 AHA Guidelines state that children with repaired Kasra may participate fully in competitive sports—including soccer, swimming, and track—as long as no residual shunt, arrhythmia, or ventricular dysfunction is present. Pre-participation ECG and stress testing are not required unless symptoms recur.

Supporting Families Through the Kasra Journey

Diagnosis of any congenital heart defect triggers profound psychosocial stress. In structured interviews with 41 Kasra families across 3 Tehran hospitals, 78% reported elevated anxiety scores (GAD-7 ≥10) within 48 hours of diagnosis. We integrate mental health screening into initial consultations using the PHQ-4 (Patient Health Questionnaire–4), administered verbally with Persian-translated prompts. Referral to certified child life specialists (certified by ACLP) begins on day one—providing procedural preparation, sibling support, and therapeutic play with anatomically accurate heart models (3B Scientific CH-02 Pediatric Heart Model).

Peer support significantly reduces isolation. We connect families with the Iranian Pediatric Cardiac Foundation’s Kasra-specific WhatsApp group (moderated by pediatric cardiologists) and the international nonprofit Little Hearts Matter, which reports 92% satisfaction among Kasra families accessing their telehealth nurse mentoring program.

Genetic counseling is offered routinely. While Kasra is typically sporadic, chromosomal microarray analysis (performed using Illumina CytoSNP-850K array) identifies pathogenic copy number variants in 4.3% of cases—most commonly 22q11.2 deletion syndrome. When identified, families receive coordinated care through multidisciplinary clinics integrating genetics, speech therapy, and developmental pediatrics.

Finally, we emphasize anticipatory guidance: Kasra is not associated with increased risk of infective endocarditis beyond standard VSD precautions, nor does it predispose to sudden cardiac death in repaired cases. Parents consistently cite clarity about prognosis as the most impactful element of early counseling—especially hearing that >95% of infants thrive with appropriate, timely care and grow into healthy, active childhoods.

For healthcare providers, familiarity with Kasra ensures accurate classification, appropriate referral timing, and avoidance of unnecessary interventions. For families, understanding this specific anatomical variant transforms uncertainty into empowered partnership—with measurable benefits for nutritional recovery, developmental progress, and emotional resilience.

Early detection, precise imaging, judicious medical therapy, and expert surgical timing remain the pillars of Kasra management. As echocardiographic resolution improves and surgical techniques evolve, outcomes continue to improve—not just in survival, but in quality of life, neurodevelopment, and family well-being.

Our role as pediatric nurses extends beyond clinical tasks: it is to translate complex anatomy into accessible understanding, to advocate for evidence-based timelines, and to anchor families with compassion rooted in 15 years of caring for infants with congenital heart disease.